Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study.
Tiede A, Hart C, Knöbl P, Greil R, Oldenburg J, Sachs UJ, Miesbach W, Pfrepper C, Trautmann-Grill K, Holstein K, Pilch J, Möhnle P, Schindler C, Weigt C, Schipp D, May M, Dobbelstein C, Pelzer FJ, Werwitzke S, Klamroth R.
Lancet Haematol. 2023 Nov;10(11):e913-e921. doi: 10.1016/S2352-3026(23)00280-6. Epub 2023 Oct 16.
Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors.
Álvarez Román MT, Kragh N, Guyot P, Wilson A, Wojciechowski P, Margas W, Wdowiak M, Santagostino E, Arnaud A.
Adv Ther. 2025 Jan;42(1):442-455. doi: 10.1007/s12325-024-03031-4. Epub 2024 Nov 22.
Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
Olasupo OO, Noronha N, Lowe MS, Ansel D, Bhatt M, Matino D.
Cochrane Database Syst Rev. 2024 Feb 27;2(2):CD014544. doi: 10.1002/14651858.CD014544.pub2.
TSUBASA Study: Evaluating Association of Physical Activity and Bleeding Events in People With Haemophilia A Without Factor VIII Inhibitors Receiving Emicizumab.
Amano K, Fujii T, Sawada A, Nagao A, Nagae C, Nojima M, Suzuki N, Kawano M, Shimura T, Sugao Y, Hattori N, Nogami K.
Haemophilia. 2025 Jul;31(4):703-712. doi: 10.1111/hae.70070. Epub 2025 Jun 18.
Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
Pipe SW, Shima M, Lehle M, Shapiro A, Chebon S, Fukutake K, Key NS, Portron A, Schmitt C, Podolak-Dawidziak M, Selak Bienz N, Hermans C, Campinha-Bacote A, Kiialainen A, Peerlinck K, Levy GG, Jiménez-Yuste V.
Lancet Haematol. 2019 Jun;6(6):e295-e305. doi: 10.1016/S2352-3026(19)30054-7. Epub 2019 Apr 16.
Nonvariceal Upper Gastrointestinal Bleeding.
Rahman SI, Saeian K.
Crit Care Clin. 2016 Apr;32(2):223-39. doi: 10.1016/j.ccc.2015.12.002. Epub 2016 Feb 12.
Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study.
Weyand AC, Meunier S, Suzuki N, Bystrická L, Neill G, Abad-Franch L, Willemze A, Tosetto A.
Am J Hematol. 2025 May;100(5):813-820. doi: 10.1002/ajh.27603. Epub 2025 Feb 10.
Endoscopic sclerotherapy.
Terblanche J, Krige JE, Bornman PC.
Surg Clin North Am. 1990 Apr;70(2):341-59. doi: 10.1016/s0039-6109(16)45085-1.
Horrific Hemorrhage: Post Tonsillectomy Bleeding Management.
Leff R, Homme JJ.
Emerg Med Clin North Am. 2025 Nov;43(4):785-799. doi: 10.1016/j.emc.2025.06.006. Epub 2025 Jul 5.
Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial.
Malec L, Mathias M, Dunn AL, Nolan B, Wong N, Bystrická L, Khan U, Neill G, Santagostino E, Gunawardena S, Tarango C, Peyvandi F.
J Thromb Haemost. 2025 Nov;23(11):3481-3491. doi: 10.1016/j.jtha.2025.07.011. Epub 2025 Jul 21.
